JP2016534022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534022A5 JP2016534022A5 JP2016503264A JP2016503264A JP2016534022A5 JP 2016534022 A5 JP2016534022 A5 JP 2016534022A5 JP 2016503264 A JP2016503264 A JP 2016503264A JP 2016503264 A JP2016503264 A JP 2016503264A JP 2016534022 A5 JP2016534022 A5 JP 2016534022A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- variable region
- set forth
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 101001074382 Homo sapiens 5'-3' exonuclease PLD4 Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000043866 human PLD4 Human genes 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 101710142129 5'-3' exonuclease PLD4 Proteins 0.000 claims 2
- 102100036183 5'-3' exonuclease PLD4 Human genes 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims 1
- 229940123121 B-cell inhibitor Drugs 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036697 Primary hypothyroidism Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047097 Vascular purpura Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 208000023652 chronic gastritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013158258 | 2013-07-30 | ||
| JP2013158258 | 2013-07-30 | ||
| PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018206702A Division JP2019014759A (ja) | 2013-07-30 | 2018-11-01 | 抗ホスホリパーゼd4抗体を含む医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534022A JP2016534022A (ja) | 2016-11-04 |
| JP2016534022A5 true JP2016534022A5 (enExample) | 2017-09-07 |
| JP6431523B2 JP6431523B2 (ja) | 2018-11-28 |
Family
ID=51493000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503264A Active JP6431523B2 (ja) | 2013-07-30 | 2014-07-30 | 抗ホスホリパーゼd4抗体を含む医薬 |
| JP2018206702A Ceased JP2019014759A (ja) | 2013-07-30 | 2018-11-01 | 抗ホスホリパーゼd4抗体を含む医薬 |
| JP2019173621A Active JP6843449B2 (ja) | 2013-07-30 | 2019-09-25 | 抗ホスホリパーゼd4抗体を含む医薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018206702A Ceased JP2019014759A (ja) | 2013-07-30 | 2018-11-01 | 抗ホスホリパーゼd4抗体を含む医薬 |
| JP2019173621A Active JP6843449B2 (ja) | 2013-07-30 | 2019-09-25 | 抗ホスホリパーゼd4抗体を含む医薬 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160168266A1 (enExample) |
| EP (1) | EP3027656B1 (enExample) |
| JP (3) | JP6431523B2 (enExample) |
| KR (1) | KR102367760B1 (enExample) |
| CN (1) | CN105745226B (enExample) |
| AU (1) | AU2014297217B2 (enExample) |
| BR (1) | BR112016002001B1 (enExample) |
| CA (1) | CA2919736C (enExample) |
| DK (1) | DK3027656T3 (enExample) |
| ES (1) | ES2736324T3 (enExample) |
| HU (1) | HUE044469T2 (enExample) |
| MX (1) | MX381725B (enExample) |
| PL (1) | PL3027656T3 (enExample) |
| RU (1) | RU2709741C2 (enExample) |
| SG (2) | SG10201800592SA (enExample) |
| TR (1) | TR201910330T4 (enExample) |
| WO (1) | WO2015016386A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| DK2809683T3 (en) * | 2012-01-31 | 2018-12-10 | Sbi Biotech Co Ltd | ANTI-phospholipase D 4 ANTIBODY |
| SG10201800592SA (en) * | 2013-07-30 | 2018-03-28 | Sbi Biotech Co Ltd | Medicament comprising anti-phospholipase d4 antibody |
| BR112019000544A2 (pt) | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
| AU2019208102B2 (en) | 2018-01-12 | 2025-10-09 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型tlr7の分析 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2091684T3 (es) * | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| WO2000011015A1 (en) * | 1998-08-24 | 2000-03-02 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
| EP1392855A4 (en) * | 2000-12-07 | 2005-05-25 | Millennium Pharm Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF VIRAL DISEASES VIA GENE 55092 |
| JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
| DK2809683T3 (en) * | 2012-01-31 | 2018-12-10 | Sbi Biotech Co Ltd | ANTI-phospholipase D 4 ANTIBODY |
| SG10201800592SA (en) * | 2013-07-30 | 2018-03-28 | Sbi Biotech Co Ltd | Medicament comprising anti-phospholipase d4 antibody |
-
2014
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 MX MX2016001193A patent/MX381725B/es unknown
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active Active
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en not_active Ceased
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534022A5 (enExample) | ||
| JP2013060443A5 (enExample) | ||
| JP2016029056A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2014111644A5 (enExample) | ||
| JP2014524733A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| JP2009519718A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| JP2013506675A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2017513813A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2007527406A5 (enExample) | ||
| RU2013140350A (ru) | Антитела против человеческого il33r и их применение | |
| EP4240758A1 (en) | Neutralizing anti-sars-cov-2 antibodies | |
| JP2012501669A5 (enExample) | ||
| JP2016516400A5 (enExample) |